Skip to Content

Fresenius SE & Co KGaA FSNUF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Fresenius SE is a healthcare holding company based in Germany with four segments. The company owns a large stake in dialysis service provider and equipment manufacturer Fresenius Medical Care, which accounted for 49% of consolidated revenue in 2019. The Kabi segment (19% of revenue) manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. At 26% of revenue, the Helios segment operates private hospitals in Germany, Spain, and Latin America. At 6% of revenue, Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.

Contact
Else-Kroener-Strasse 1
Bad Homburg v.d.H, 61352, Germany
T +49 61726080
Sector Healthcare
Industry Medical Care Facilities
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 309,114